https://www.taxtmi.com/news?id=13746 A compulsory licence was granted for an anti cancer drug containing Sorafenib Tosylate, permitting domestic manufacture despite a patent held by the original patentee under statutory compulsory licence provisions. Subsequent ministerial recommendations to consider compulsory licences for three other oncology drugs prompted inter ministerial scrutiny: one patent lapsed, one drug was found unsafe by health authorities, and further information was requested for the remaining candidate before any compulsory licensing action. en-us Fri, 19 Dec 2014 17:20:54 +0530 Fri, 19 Dec 2014 17:20:54 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=13746 A compulsory licence was granted for an anti cancer drug containing Sorafenib Tosylate, permitting domestic manufacture despite a patent held by the original patentee under statutory compulsory licence provisions. Subsequent ministerial recommendations to consider compulsory licences for three other oncology drugs prompted inter ministerial scrutiny: one patent lapsed, one drug was found unsafe by health authorities, and further information was requested for the remaining candidate before any compulsory licensing action. News - Fri, 19 Dec 2014 17:20:54 +0530 https://www.taxtmi.com/news?id=13746